Appeal No. 2000-1783 Page 2
Application No. 08/817,719
multiple sclerosis, diabetes, uveitis, dermatitis, psoriarsis, urticaira, nephrotic syndrome,
glomerulonephritis, inflammatory bowel disease, ulcerative colitis, Crohn=s disease,
Sjogren=s syndrome, asthma, eczema, graft vs host disease or insulitis.
The references relied on by the examiner are:
Bonnefoy et al. (Bonnefoy), AInhibition of Human Interleukin 4-Induced IgE Synthesis by
a Subset of Anti-CD23/FcεRII Monoclonal Antibodies,@ Eur. J. Immunol., Vol. 20, pp.
139-144 (1990)
Reiter et al. (Reiter), ATreatment of Rheumatoid Arthritis with Monoclonal CD4 Antibody
M-T151,@ Arthritis and Rheumatism, Vol. 34, No. 5, pp. 525-536 (May 1991)
Hawkins et al. (Hawkins), AAdapting Antibodies for Clinical Use,@ BJM, Vol. 305, pp.
1348-132 (1992)
Burmester et al (Burmester), AAnti-CD4 Therapy in Rheumatoid Arthritis,@ Clinical and
Experimental Rheumatology, Vol. 11 (Suppl. 8), pp. S139-s145 (1993)
Flores-Romo et al. (Flores-Romo), AInhibition of an in Vivo Antigen-Specific IgE
Response by Antibodies to CD23,@ Science, Vol. 261, pp. 1083-1041 (August 1993)
Bansal et al (Bansal), AIncreased Levels of sCD23 in Rheumatoid Arthritis are Related
to Disease Status,@ Clinical and Experimental Rheumatology, Vol. 12, pp. 281-285
(1994)
Armant et al. (Armant), ARegulation of Cytokine Production by Soluble CD23:
Costimulation of Interferon γ Secretion and Triggering of Tumor Necrosis Factor α
Release,@ J. Exp. Med., Vol. 180, pp. 1005-1011 (September 1994)
The claims stand rejected as follows:
I. Claims 14-20 under the first paragraph of 35 U.S.C. ' 112 (enablement).
II. Claims 14, 15 and 18-21 under 35 U.S.C. ' 103 as unpatentable over Bansal,
Flores-Romo, Bonnefoy or Armant.
III. Claims 14, 15 and 18-26 under 35 U.S.C. ' 103 as unpatentable over
Bansal, Flores-Romo, Bonnefoy or Armant in view of Reiter or Burmester.
IV. Claims 14-21 under 35 U.S.C. ' 103 as unpatentable over Bansal, Flores-
Romo, Bonnefoy or Armant in view of Hawkins.
BACKGROUND
CD23, the low affinity receptor for IgE, Ahas pleiotropic activities including
Page: Previous 1 2 3 4 5 6 7 8 9 10 Next
Last modified: November 3, 2007